Merck Ignores Molnupiravir’s Cytotoxicity

Merck has just applied to the FDA for an emergency use authorization of Molnupiravir for early treatment of COVID-19.

Molnupiravir is a mutagenic nucleotide analogue.

It increases the rate of mutations in the coronavirus’ RNA and in human DNA.

The application is based on alleged interim results of an unfinished trial, where this drug was given to 385 patients in 173 sites all over the world, and the patients were then observed for 29 days since recruitment and randomization.

Molnupiravir is mutagenic and toxic for human cells.

Merck and Ridgeback Biotherapeutics have flatly denied this and proceeded with human trials.

The consequences of Molnupiravir’s DNA mutagenesis, such as cancer or birth defects, take months or years to develop.

The 24 days of patient observation after 5 days treatment is obviously not enough to detect anything.

The broad use of Molnupiravir is a global catastrophic risk because the increased rate of coronavirus mutations is likely to create more dangerous variants.

Source: LeoG – Trial Site News

Published by